|
PSCI-24-018 |
Phase 1, open label clinical trial to treat Stage IV cancer patients with multiple patient-specific mutated cell surface proteins with chimeric antibodies |
|
PSCI-24-021 |
BINGO: Bridging Knowledge, Increasing Awareness - Empowering the Black Community through Educational Gamification on Cancer Screenings and Clinical Trial Diversity |
|
PSCI-24-027 |
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients With Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur) A022101 |
|
PSCI-24-028 |
NRG-BR008: A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO) |
|
PSCI-24-032 |
Exploring Patient Level Barriers and Facilitators for Human Papillomavirus Vaccine Opportunities in Young Adult Survivors of Childhood Cancer in Rural Pennsylvania |
|
PSCI-24-040 |
NRG-CC008 A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk] |
|
PSCI-24-041 |
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence -A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT) |
|
PSCI-24-043 |
Adapting an Advance Care Planning Intervention for Use with Patients with Cancer and their Care partners: Phase Two |
|
PSCI-24-051 |
Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete or Partial Responders |
|
PSCI-24-052 |
A Dose Escalation Study Using Difluoromethylornithine (DFMO) and AMXT-1501 followed by a Randomized Controlled Trial of DFMO with or without AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas |
